Author
@BioStocks BioStocks
grade Cx.com/BioStocks ↗
High-volume biotech catalyst news desk relaying FDA, trial, and pharma M&A flow
Aggregates and relays real-time biotech/pharma catalysts — F
trader score
-0.39
hit rate
60%
mean α
-0.66%
signals 14d
104
Grade = how their written analysis reads (A best). Trader score = how their last-20 timestamped calls performed vs SPY.
Their picks, scored
Across their last 20 scored bets: 60% hit rate, -0.66% mean alpha, trader score -0.39. Their last-14d mentions, direction-adjusted, have moved +2.4% since posting (mean over 45 mentions with price data).
Recent signals15receipts included
| date (PT) | ticker | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|---|
| 2026-07-02 | RVMD | @BioStocks | +0.25 | RVMD presents Phase 1/2 clinical data for zoldonrasib combinations at ESMO. | — | tweet ↗ |
| 2026-07-02 | ABVX | @BioStocks | +0.35 | Truist raised ABVX price target to $155. | — | tweet ↗ |
| 2026-07-02 | LRMR | @BioStocks | +0.45 | HCW initiated LRMR with Buy and $10 price target. | · | tweet ↗ |
| 2026-07-02 | UTHR | @BioStocks | -0.10 | UTHR acquires Thymmune Therapeutics for $140M in cash. | — | tweet ↗ |
| 2026-07-02 | ABVX | @BioStocks | +0.15 | ABVX underwriters exercised over-allotment option in full, raising $920M. | — | tweet ↗ |
| 2026-07-01 | VRTX | @BioStocks | +0.55 | FDA approves first gene therapy for young children with SCD. | +6.0% | tweet ↗ |
| 2026-07-01 | CRSP | @BioStocks | +0.35 | FDA approves first gene therapy for young children with SCD. | +8.0% | tweet ↗ |
| 2026-07-01 | UNCY | @BioStocks | +0.20 | Noble Capital maintains Outperform but lowers PT to 50. | · | tweet ↗ |
| 2026-07-01 | ABVX | @BioStocks | +0.30 | Reports ABVX cash runway into Q2 2029. | +9.1% | tweet ↗ |
| 2026-07-01 | HIMS | @BioStocks | +0.40 | BofA raised HIMS PT to 36 from 25. | -2.0% | tweet ↗ |
| 2026-07-01 | GUTS | @BioStocks | +0.45 | Craig-Hallum initiated GUTS with Buy and PT 4. | · | tweet ↗ |
| 2026-07-01 | BBIO | @BioStocks | +0.20 | BBIO raises $1B preferred equity led by Sixth Street and KKR. | +3.6% | tweet ↗ |
| 2026-07-01 | KZIA | @BioStocks | +0.45 | BTIG initiated KZIA with Buy and PT 34. | · | tweet ↗ |
| 2026-07-01 | NGNE | @BioStocks | -0.15 | NGNE $125M offering priced at $30 per share. | · | tweet ↗ |
| 2026-07-01 | CANF | @BioStocks | +0.55 | CANF Phase 2a pancreatic cancer study achieved safety endpoint and durable survival outcomes. | · | tweet ↗ |
Grade is our human read-worthiness rating; trader score is a rolling 20-bet hit-rate/alpha composite — different things, often disagreeing. “Since then” is direction-unaware in the table; the summary line above adjusts for which way they leaned.